Retatrutide vs Phentermine: How They Compare in 2026
Retatrutide is an investigational medication in clinical trials. It is not FDA-approved, is not legally compoundable, and is not available through Trimi. Trimi does not offer it and has no plans to. This article is editorial safety coverage for people researching the drug-development pipeline.
Retatrutide and phentermine sit at opposite ends of the weight loss medication timeline, and in 2026 only one of them can be prescribed. Phentermine is an FDA-approved appetite suppressant that has been on the market since 1959, is available as an inexpensive generic, and remains one of the most prescribed anti-obesity drugs in the United States. Retatrutide is Eli Lilly's investigational triple agonist, still moving through the phase 3 TRIUMPH program, with no approval and no legal route to a prescription. This article compares the two molecules on mechanism, evidence, status, and safety, and explains what that asymmetry means for anyone weighing real options today.
How Retatrutide and Phentermine Work
Retatrutide is a once-weekly injectable that activates three metabolic hormone receptors, GIP, GLP-1, and glucagon, while phentermine is a once-daily oral stimulant that suppresses appetite by increasing norepinephrine activity in the brain. That single sentence captures most of the practical difference. Retatrutide's incretin-based mechanism works through the body's own satiety and glucose-regulation signaling, and its half-life of approximately 6 days is what supports once-weekly dosing. Phentermine is a sympathomimetic amine, chemically related to amphetamine, with a much shorter duration of action that requires daily dosing and produces stimulant effects alongside appetite suppression.
What the Evidence Shows
The headline numbers are far apart. According to the 2023 NEJM phase 2 trial (Jastreboff et al.), retatrutide produced a mean weight reduction of up to 24.2% at 48 weeks at the highest dose. Phentermine's evidence base, much of it from older and shorter studies, typically shows 5-10% weight loss over courses of roughly 12 to 36 weeks.
Those numbers deserve honest context. Retatrutide's figure comes from a phase 2 trial with a few hundred participants; phase 3 TRIUMPH results have not been published, and phase 2 results sometimes shrink in larger trials. For anchoring against approved incretin therapies: the STEP 1 trial reported 14.9% mean weight reduction with semaglutide 2.4 mg at 68 weeks, and SURMOUNT-1 reported 20.9% with the highest tirzepatide dose at 72 weeks. All of these are separate trials in separate populations, so ranking molecules across them is indirect at best. For a full comparison of the approved incretin class against phentermine, see our GLP-1 vs phentermine 2026 comparison.
Approval Status: The Asymmetry That Decides Everything
Phentermine is FDA-approved, generic, and prescribable today; retatrutide is investigational and unavailable outside clinical trials. This is not a footnote, it is the deciding fact of the comparison. Phentermine's approval covers short-term use, generally up to about 12 weeks, and it is a Schedule IV controlled substance. Retatrutide has completed phase 2 and is in phase 3 TRIUMPH trials, which anyone can follow on clinicaltrials.gov. Because it is an investigational drug without an approved reference product, it also cannot be legally compounded under FDA compounding rules. Vials sold online as "research" retatrutide sit outside any regulated supply chain, with no verification of identity, dose, or sterility.
Side-by-Side Comparison
| Factor | Retatrutide | Phentermine |
|---|---|---|
| Mechanism | Triple incretin agonist (GIP, GLP-1, glucagon receptors) | Sympathomimetic stimulant (norepinephrine release) |
| Dosing form | Once-weekly subcutaneous injection (half-life approximately 6 days) | Once-daily oral tablet or capsule |
| Best evidence | Phase 2 (NEJM 2023): up to 24.2% mean weight reduction at 48 weeks | Typically 5-10% loss in short-term studies |
| Regulatory status | Investigational, phase 3 (TRIUMPH), not approved, unavailable | FDA-approved for short-term use; generic; Schedule IV |
| Common side effects | Gastrointestinal: nausea, vomiting, diarrhea, constipation | Stimulant-type: raised heart rate and blood pressure, insomnia, dry mouth |
Side Effect Profiles
Retatrutide's side effects in trials look like the rest of the incretin class, mostly gastrointestinal, while phentermine's cluster around its stimulant activity. In the phase 2 trial, nausea, vomiting, diarrhea, and constipation were the most common adverse events, generally dose-related and concentrated during titration. Incretin-class safety context also applies: pancreatitis and gallbladder disease have been reported with GLP-1 receptor agonists, severe vomiting or diarrhea with dehydration can contribute to acute kidney injury, and the class carries a boxed warning about thyroid C-cell tumors observed in rodent studies, which is why a personal or family history of medullary thyroid carcinoma is a standard exclusion.
Phentermine's cautions are cardiovascular and neurological: elevated heart rate and blood pressure, insomnia, restlessness, and dry mouth. It is generally avoided in people with cardiovascular disease, uncontrolled hypertension, or hyperthyroidism, and its Schedule IV status reflects some potential for dependence. Neither profile is trivial; they are simply different, and they call for different screening by a prescribing clinician.
Who Might Be a Candidate for Each
In 2026 the practical decision is not retatrutide versus phentermine, because nobody outside a clinical trial can choose retatrutide. A clinician weighing today's options is really choosing between phentermine and the approved incretin class. Phentermine may fit someone who wants a short, low-cost, pill-based course and has no cardiovascular risk factors. Incretin therapies fit a chronic-disease treatment model, and in trials of the branded formulations, semaglutide and tirzepatide produced larger and more durable average weight loss than short-term phentermine courses. Licensed clinicians can prescribe compounded semaglutide or compounded tirzepatide when appropriate. People specifically interested in retatrutide can follow the TRIUMPH program on clinicaltrials.gov and read our related coverage on protein intake and intermittent fasting while the data mature.
Available today by prescription
Looking for a medication you can actually get now?
Retatrutide is still in clinical trials and is not available anywhere outside of them. If you want treatment that you can actually start today, licensed clinicians can prescribe compounded semaglutide ($99/month on the annual plan) or compounded tirzepatide ($125/month on the annual plan) when appropriate, with provider review, medication, and shipping included.
Start your online visitFrequently Asked Questions
Is retatrutide stronger than phentermine?
The trial data point that way, with caveats. According to the 2023 NEJM phase 2 trial (Jastreboff et al.), retatrutide produced a mean weight reduction of up to 24.2% at 48 weeks at the highest dose, while phentermine studies typically show 5-10% loss over short courses. These are different trials in different populations, so the comparison is indirect, and retatrutide's phase 3 results are still pending.
Can I actually choose between retatrutide and phentermine in 2026?
No. Phentermine is FDA-approved and prescribable today. Retatrutide is an investigational drug still in phase 3 trials (the TRIUMPH program) and is not available by prescription anywhere. The only legitimate way to take it is enrollment in a clinical trial listed on clinicaltrials.gov.
Why is phentermine only approved for short-term use?
Phentermine's FDA approval covers short-term use, generally a few weeks to about 12 weeks, because it is a sympathomimetic stimulant with cardiovascular effects such as raised heart rate and blood pressure, and because it is a Schedule IV controlled substance with some potential for dependence. Long-term safety data are limited.
How does retatrutide compare with semaglutide and tirzepatide?
Among approved incretin therapies, the STEP 1 trial reported 14.9% mean weight reduction with semaglutide 2.4 mg at 68 weeks, and SURMOUNT-1 reported 20.9% at the highest tirzepatide dose at 72 weeks. Retatrutide's phase 2 figure of up to 24.2% at 48 weeks is higher, but it comes from an earlier-stage trial, and cross-trial comparisons are indirect.
Do phentermine and retatrutide have the same side effects?
No, their side-effect profiles are very different. Retatrutide's trial data show mostly gastrointestinal effects such as nausea, vomiting, and constipation, consistent with the incretin class. Phentermine's side effects track its stimulant mechanism: elevated heart rate and blood pressure, insomnia, dry mouth, and restlessness.
This article is general information, not medical advice. It does not cover every risk, interaction, or individual circumstance. Talk with a licensed clinician before starting, stopping, or comparing any weight loss medication.
Sources & References
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM 2023. pubmed.ncbi.nlm.nih.gov/37366315
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. pubmed.ncbi.nlm.nih.gov/33567185
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. pubmed.ncbi.nlm.nih.gov/35658024
- U.S. Food and Drug Administration. Human Drug Compounding. fda.gov/drugs/human-drug-compounding
- ClinicalTrials.gov, U.S. National Library of Medicine. clinicaltrials.gov